MM-151   Click here for help

GtoPdb Ligand ID: 9125

Compound class: Antibody
Comment: MM-151 is a mixture of three fully human IgG1 monoclonal antibodies, each of which targets a distinct (and nonoverlapping) epitope on the extra-cellular domain of the EGFR [2]. This can be termed an oligoclonal agent. It was designed to target EGFRs with treatment-induced (acquired) resistance mutations that develop in cancer patients treated with the approved anti-EGFR monoclonals cetuximab or panitumumab. Development of the three antibody components is reported in [1].
No information available.
Summary of Clinical Use Click here for help
A Phase 1 safety study of MM-151 in patients with advanced, treatment resistant solid tumours has been completed (NCT01520389). A further Phase 1 trial (NCT02538627) is evaluating MM-151 in combination with the ERBB3 (HER3) candidate drug seribantumab (MM-121).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01520389 Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Phase 1 Interventional Merrimack Pharmaceuticals
NCT02538627 Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib Phase 1 Interventional Merrimack Pharmaceuticals